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Background. We sought to determine and compare the prevalence of the Metabolic Syndrome (MS) in patients with acute
myocardial infarction (AMI) utilizing the new International Diabetes Federation (IDF) deﬁnition with the older National
Cholesterol Education Program (NCEP) deﬁnition. We also examined the clinical utility of MS in this context. Methods.At o t a lo f
107 consecutive patients with AMI were prospectively evaluated for MS. Fasting lipids obtained at admission and fasting glucose at
discharge were used. A postdischarge folder audit veriﬁed rates of discharge coding and implementation of speciﬁc management
strategies for MS. Results. Baseline patient characteristics included: mean age 59 ± 13 years; males 80%; diabetes 19%; mean BMI
29.7 ± 8.4kg/m 2. MS prevalence was 54% by the IDF deﬁnition and 49% by the NCEP deﬁnition, with good agreement between
deﬁnitions: κ = 0.664, P<. 001. Factors predictive of MS after multivariate analysis included: hypertension, fasting glucose, waist
circumference, and serum HDL (all P<. 05). Despite the high prevalence, MS was recognized at discharge in only 1 patient,
and referral for exercise and/or weight-loss programs was undertaken in 5 patients. Conclusion. There is a high prevalence of MS
utilizing contemporary deﬁnitions in patients with AMI: 54% by the IDF deﬁnition and 49% by NCEP criteria. Despite the high
prevalence, MS was under-recognized and under-treated in this population.
1.Introduction
The metabolic syndrome (MS) has been shown to be a
powerful and potentially modiﬁable risk factor for coronary
artery disease as well as diabetes [1–3]. There is limited data
on the prevalence of MS in patients with acute myocardial
infarction (AMI) utilizing contemporary deﬁnitions [4]. In
particular, no study has previously reported the prevalence
of MS in this population using the International Diabetes
Federation (IDF) deﬁnition, which critically diﬀers from
previous deﬁnitions in that it emphasizes central obesity as
the essential criterion for MS diagnosis [5]. In addition, no
previous study has focused on the clinical utility of MS to
physicians in the routine management of patients with AMI.
The aim of the present study was to determine and
compare the true prevalence of MS in patients with AMI
utilizing the new “obesity-centric” IDF deﬁnition with the
older National Cholesterol Education Program (NCEP)
deﬁnition. We also sought to examine the clinical utility
of the MS concept in this context by reviewing rates of
clinical diagnosis and institution of speciﬁc management
strategies for MS by clinicians managing patients with AMI.
We hypothesized that, given the composite deﬁnition of
MS incorporating well-recognized cardiac risk factors, a
high prevalence of MS would be noted in this popula-
tion, and that rates of clinical detection would be low
owing to variation in deﬁnitions and controversy about
etiology.2 Cardiology Research and Practice
2.MaterialsandMethods
We conducted a prospective observational study involving
107 consecutive patients with acute ST-elevation myocardial
infarction (STEMI) admitted to the coronary care unit
of a regional tertiary referral center between May and
November 2007. All patients were referred for primary
percutaneous coronary intervention (PCI) and had prompt
coronary angiography as per protocol. Fasting lipid assays
(total cholesterol (T-Chol), high-density lipoprotein choles-
terol (HDL-C), low-density lipoprotein cholesterol (LDL-
C), triglycerides (Trig)) were performed the morning after
admission (within 24 hours of admission). Fasting glucose
was performed on day 4 post admission or day prior to
discharge whichever was later. Patients were reviewed on
the ward and anthropometric measurements including waist
circumference, hip circumference, height, and weight were
obtained on day of discharge. All patients were referred for
echocardiography prior to discharge as per ward protocol.
The presence of the MS was determined according to
the two most contemporary deﬁnitions: the International
Diabetes Federation (IDF) consensus deﬁnition (2006) and
the National Cholesterol Education Panel (NCEP) deﬁnition
(2001) (see below for deﬁnitions). Following discharge of
patients from the ward, a folder audit was carried out
to determine rates of discharge diagnosis coding of MS.
Speciﬁc aspects of the recommended management of MS
werealsoaudited,namely,referralfordietaryadvice,exercise
programs, and/or weight loss programs. All data collection
was performed by researchers independent of the clinical
teams involved in patient care. All blood assay results were
available to the clinical teams involved in patient care, and
internists were alerted to abnormal fasting glucose levels
for referral to inpatient diabetes services. Angiographic and
echocardiographic data are reported as documented in the
ﬁnal reports produced by the reporting cardiologist blinded
to MS status.
Serum lipid measurements were made from 5mls of
blood collected in a SST gel vacutainer. Serum glucose
measurements were made from 2mls of blood collected in
a Sodium Fluoride EDTA vacutainer. All serum assays were
performed on a Beckman-Coulter Unicel DxC800 analyzer
(Fullerton, California, USA). Glucose measurements were
obtained enzymatically using the glucose oxidase method.
T-Chol and HDL-C measurements were obtained enzymat-
ically using the cholesterol oxidase method. Triglyceride
(Trig) measurements were obtained enzymatically using
glycerol kinase and glycerophosphate oxidase method. LDL-
C levels were derived using the formula: LDL-C = T-Chol –
HDL-C – Trig/2.25.
2.1. Deﬁnitions. MS according to the IDF deﬁnition (IDF-
MS) was deﬁned as per current guidelines as having ethnic-
speciﬁc waist circumference (WC) cutoﬀ values as the mea-
sure of central obesity, plus any two of raised triglycerides
≥150mg/dL (1.7mmol/L) or speciﬁc treatment for this
abnormality, reduced high-density lipoprotein cholesterol
(HDL-cholesterol) <40mg/dL (1.03mmol/L) in men and
<50mg/dL (1.29mmol/L) in women or speciﬁc treatment
forthisabnormality,raisedbloodpressure(BP) ≥130mmHg
systolic and ≥85mmHg diastolic or treatment of previously
diagnosed hypertension, and raised fasting plasma glucose
(FPG) ≥100mg/dL (5.6mmol/L) or previously diagnosed
diabetes [6].
The metabolic syndrome according to the NCEP def-
inition (NCEP-MS) was deﬁned as per current guidelines
as having a cluster of at least 3 of the following char-
acteristics: fasting glucose ≥110mg/dL (6.0mmol/L) or
taking medications for diabetes, central obesity with WC
>102cm in men and >88cm in women, raised triglycerides
≥150mg/dL(1.7mmol/L),lowHDL-cholesterol<40mg/dL
(1.03mmol/L) in men and <50mg/dL (1.29mmol/L) in
women, or raised BP ≥135mmHg systolic and ≥85mmHg
diastolic or previously diagnosed hypertension [7].
Those with a preadmission diagnosis of diabetes were
considered to have established diabetes. New impaired
fasting glucose (IFG) was deﬁned as a predischarge fasting
plasma glucose of ≥100mg/dL (5.6mmol/L) in patients
without pre-existing diabetes [8]. Obesity was deﬁned as
a body-mass index (BMI) ≥30kg/m2 [9]. Hypercholes-
terolemia was deﬁned as fasting serum total cholesterol of
≥4.5mmol/L [7]. ECG criteria for STEMI was in accordance
with currently accepted guidelines: ST elevation ≥1mm
in two contiguous limb leads, ≥2mm in two contiguous
chest leads, or new onset left bundle branch block (LBBB)
[10]. Signiﬁcant coronary disease was deﬁned as luminal
narrowing of ≥50% on angiography
2.2. Statistical Analysis. Data was analysed using SPSS for
Windows version 14.0 (SPSS Inc, Chicago, Illinois). Categor-
ical variables are presented as percentages and continuous
variables as mean ± standard deviation. Group diﬀerences
were assessed using Student’s t-test for continuous variables
and Fisher’s exact test for categorical variables. Agreement
between the 2 deﬁnitions of MS was assessed using Cohen’s
Kappa (κ). Logistic regression analysis with stepwise selec-
tion with inclusion of variables at the 5% level and removal
atthe10%levelateachstepwasusedtoidentifyindependent
predictors of MS from baseline patient characteristics and
laboratory ﬁndings. Both forwards and backwards selection
were used to arrive at the same model. A P value <.05 was
considered statistically signiﬁcant.
2.3. Ethical Considerations. This study was approved by the
institutionalethicalreviewcommittee,andinformedconsent
was obtained from each patient before participation.
3. Results
The baseline patient characteristics of the 107 patients
enrolled in this study are listed in Table 1. The mean age
was 59 ± 13 years, and 80% were males. The predominant
ethnic grouping was Europid (n = 79; 74%). Pre-existing
hypertension was the most common cardiac risk factor,
foundin51patients(48%).Pre-existingdiabeteswaspresent
in 20 patients (19%). New IFG in patients without pre-
existing diabetes was found in 42 patients (39%). Base-
line anthropometric measurements suggested an overweightCardiology Research and Practice 3
Table 1: Baseline characteristics of patients.
Baseline Characteristic N = 107
Age (years) 59 ± 13
Male 86 (80)
Ethnicity
Europid 79 (74)
South Asian 13 (12)
Eastern Mediterranean 5 (5)
Arabic 4 (4)
Chinese 4 (4)
South American 1 (1)
Polynesian 1 (1)
Hypertension 51 (48)
Smoking 20 (19)
Diabetes mellitus 20 (19)
Family history 34 (32)
Dyslipidaemia 43 (40)
Statin on admission 19 (18)
New IFG 42 (39)
Waist Circumference (cm)
Males 101.6 ± 12.8
Females 100.4 ± 18.3
Height (cm)
Males 1.70 ± 0.11
Females 1.57 ± 0.09
Weight (kg)
Males 85.0 ± 16.2
Females 72.2 ± 19.9
BMI (kg/m2)
Males 29.8 ± 8.5
Female 29.4 ± 8.3
Waist: Hip 1.08 ± 0.97
Systolic BP 112.8 ± 15.1
Diastolic BP 66.9 ± 9.5
Discharge Medications
Aspirin 91 (85)
Statin 93 (87)
Fibrate 2 (2)
Ezetimibe 3 (3)
Beta blocker 90 (84)
ACE-Inhibitor 76 (71)
ATRA 9 (8)
Clopidogrel 92 (86)
Data are presented as mean ± SD or n (%); BMI: body mass index; IFG:
impaired fasting glucose.
population with a mean BMI of 29.7 ± 8.4kg/m2. Baseline
serum lipid measurements on day 1 of admission were total
cholesterol 4.7 ± 1.3mmol/L, HDL 1.0 ± 0.3mol/L, LDL 3.0
± 1.1mmol/L, triglycerides 1.5 ± 0.8mmol/L.
A total of 58 patients (54%) met the criteria for IDF
MS. A comparison of patients with and without IDF MS
is presented in Table 2. Signiﬁcant diﬀerences on univariate
NCEP MS
n = 6
(9%)
n = 46
(72%)
n = 12
(19%)
IDF MS
κ = 0.664,P<. 001
IDF: international diabetes federation;
NCEP: national cholesterol education program
Figure 1: Prevalence of the metabolic syndrome according to
diﬀerent deﬁnitions.
analysiswerenotedbetweenthe2groupsintheprevalenceof
hypertension, pre-existing diabetes, and new IFG in terms of
clinicalcharacteristics;waistcircumference,weight,andBMI
in terms of anthropometric measurements; fasting glucose,
HDL, and triglycerides in term of laboratory measurements.
While no diﬀerences were noted between the 2 groups in
terms of systolic function measured by the left ventricular
ejection fraction, a shorter deceleration time (DT) (DT
174.0 ± 61.7 versus 206.0 ± 58.0ms, P = .02) on Doppler
echocardiography and a lower E
  velocity on tissue Doppler
(5.2 ± 1.6m/s and 6.5 ± 2.0m/s, P = .04) suggested
greater diastolic impairment in the MS group. There were no
diﬀerences between the 2 groups in the extent of coronary
disease and coronary ﬂow post PCI.
A total of 52 patients (49%) met the criteria for NCEP
MS. A comparison of patients with and without NCEP MS
is presented in Table 3. Signiﬁcant diﬀerences on univariate
analysis were noted between the 2 groups in terms of
age, gender, hypertension new IFG in terms of clinical
characteristics; waist circumference and weight in terms of
anthropometric measurements; fasting glucose, HDL and
triglycerides in terms of laboratory measurements. While no
diﬀerences were noted between the 2 groups in terms of
systolic function measured by the left ventricular ejection
fraction, indices of diastolic function assessed by tissue
Doppler suggested greater diastolic impairment in the MS
group: E
  velocity 5.4 ± 1.6 versus 6.3 ± 1.9m/s, P = .046
and E to E
  ratio 14.8 ± 5.5 versus 11.8 ± 4.1, P = .014.
There were no diﬀerences between the 2 groups in the extent
of coronary disease and coronary ﬂow post PCI.
The agreement between deﬁnitions for the presence of
MS is illustrated in Figure 1. Out of the 64 patients (60%)
who had MS by either deﬁnition, 46 patients (72%) had MS
by both deﬁnitions, 12 patients (19%) had MS by the IDF
deﬁnition only, and 6 patients (9%) had MS by the NCEP
deﬁnitiononly.ThenumberofpatientswithoutMSbyeither
deﬁnition was 43 (40%). Cohen’s Kappa for the agreement4 Cardiology Research and Practice
Table 2: Characteristics of patients with and without IDF MS.
Baseline Characteristic IDF MS (n = 58) No. MS (n = 49) P value
Age 59.7 ± 12.9 58.9 ± 12.7 NS
Male 44 (76) 42 (86) NS
Hypertension 38 (66) 13 (27) <.001
Smoking 20 (35) 22 (45) NS
Diabetes mellitus 15 (26) 5 (10) .03
Family history 20 (35) 14 (29) NS
Dyslipidaemia 21 (36) 22 (45) NS
New IFG 29 (50) 13 (27) .02
Waist Circumference 107.8 ± 13.2 92.8 ± 17.9 <.001
Height 1.7 ± 0.1 1.7 ± 0.1 NS
Hip 104.1 ± 17.5 97.6 ± 16.9 .056
Weight 89.0 ± 17.4 74.9 ± 14.6 <.001
BMI 31.2 ± 5.9 27.9 ± 10.5 .048
Waist:Hip 1.18 ± 1.31 0.96 ± 0.96 NS
Systolic BP 113.8 ± 16.3 111.6 ± 13.8 NS
Diastolic BP 67.4 ± 10.8 66.3 ± 7.9 NS
Proximal LAD Disease 29 (52) 26 (54) NS
Extent CAD NS
1 VD 14 (25) 18 (37)
2 VD 20 (36) 16 (33)
3 VD 22 (38) 14 (29)
Final TIMI 3 ﬂow 50 (91) 42 (88) NS
LVEF 43.7 ± 7.4 42.5 ± 8.8 NS
DT 174.0 ± 61.7 206.0 ± 58.0 .02
E
  5.2 ± 1.6 6.5 ± 2.0 .04
Et oE
  ratio 13.9 ± 5.0 12.4 ± 4.8 NS
Fasting Glucose 6.8 ± 2.6 5.6 ± 0.8 .002
TC 4.8 ± 1.5 4.4 ± 0.9 NS
HDL 0.9 ± 0.3 1.1 ± 0.3 .01
LDL 3.1 ± 1.3 2.8 ± 0.8 NS
Trig 1.7 ± 0.9 1.2 ± 0.7 .001
Data are presented mean ± SD or n (%). BMI: body mass index; CAD: coronary artery disease; DT: deceleration time; HDL: high-density lipoprotein; IFG:
impaired fasting glucose; LAD: left anterior descending artery; LDL: low-density lipoprotein; LVEF: left ventricular ejection fraction; TC: total cholesterol;
VD: vessels diseased.
between the 2 deﬁnitions for the presence of MS was κ =
0.664, P<. 001, suggestive of a moderately high degree of
agreement between these two contemporary deﬁnitions.
AcomparisonofthenumberoffeaturesofMSotherthan
waist circumference in patients with and without central
obesity as deﬁned by the obesity centric IDF deﬁnition
showed that patients who exceeded the waist circumference
cutoﬀs( n = 85; 79%) had signiﬁcantly higher number of
other features (2.2 ± 1.2 versus 1.5 ± 1.2, P = .028) of
MS, suggesting a role for causation linked to central obesity.
From these 85 patients (79%) who exceeded the IDF waist
circumference cutoﬀ, 58 (68%) satisﬁed the criteria for IDF
MS.
Multivariate predictors of MS are presented in Table 4.
For NCEP MS, hypertension, serum fasting glucose, serum
triglyceride levels, and waist circumference remained predic-
tiveofMS.SerumHDLlevelsandmalegenderwereinversely
related to the presence of MS. For IDF MS, hypertension,
waist circumference and serum fasting glucose remained
predictive of MS, while serum HDL levels were inversely
related.
The results of the postdischarge folder audit showed that
while 64 patients (60%) had MS by either deﬁnition, it was
clinically recognized on discharge in only 1 patient (1%).
Referral for exercise or weight loss programs was undertaken
in 5 patients (5%) only. While all patients received brief
generic dietary advice following their AMI, speciﬁc referral
to a dietitian was only undertaken in 17 patients (16%).
4. Discussion
The present study provides a ﬁrst assessment of the preva-
lence of MS in patients with AMI using the “obesity-centric”
IDF deﬁnition and compares it to the prevalence using
the more traditional NCEP deﬁnition. The main ﬁnding of
this study is that there is a high prevalence of MS usingCardiology Research and Practice 5
Table 3: Characteristics of patients with and without NCEP MS.
Baseline Characteristic NCEP MS (n = 52) No. MS (n = 55) P value
Age 62.0 ± 13.5 56.8 ± 11.6 .035
Male 35 (67) 51 (93) .001
Hypertension 37 (71) 14 (26) <.001
Smoking 15 (29) 27 (49) .05
Diabetes mellitus 15 (29) 5 (9) NS
Family history 15 (29) 19 (35) NS
Dyslipidaemia 25 (46) 18 (33) NS
New IFG 29 (59) 13 (24) .001
Waist Circumference 107.2 ± 15.3 94.1 ± 16.2 <.001
Height 1.67 ± 0.12 1.68 ± 0.12 NS
Hip 104.4 ± 19.3 98.0 ± 15.1 .062
Weight 87.5 ± 19.9 77.9 ± 13.8 .005
BMI 31.3 ± 6.3 28.1 ± 9.8 .056
Waist:Hip 1.2 ± 1.4 1.0 ± 0.2 NS
Systolic BP 114.0 ± 16.9 111.6 ± 13.3 NS
Diastolic BP 66.4 ± 10.8 67.3 ± 8.2 NS
Proximal LAD Disease 26 (52) 29 (53) NS
Extent CAD NS
1 VD 15 (30) 17 (32)
2 VD 16 (32) 20 (37)
3 VD 19 (38) 17 (32)
Final TIMI 3 ﬂow 45 (92) 47 (87) .4
LVEF (%) 44.2 ± 7.3 42.1 ± 8.7 NS
DT 179.6 ± 65.9 197.5 ± 57.1 NS
E
  5.4 ± 1.6 6.3 ± 1.9 .046
Et oE
  ratio 14.8 ± 5.5 11.8 ± 4.1 .014
Fasting Glucose 7.1 ± 2.7 5.6 ± 0.8 <.001
TC 4.9 ± 1.5 4.4 ± 1.0 .082
HDL 0.94 ± 0.29 1.06 ± 0.27 .037
LDL 3.1 ± 1.3 2.8 ± 0.8 NS
Trig 1.8 ± 0.8 1.2 ± 0.8 <.001
Data are presented mean ± SD or n (%). BMI: body mass index; CAD: coronary artery disease; DT: deceleration time; HDL: high-density lipoprotein; IFG:
impaired fasting glucose; LAD: left anterior descending artery; LDL: low-density lipoprotein; LVEF: left ventricular ejection fraction; TC: total cholesterol;
VD: vessels diseased.
Table 4: Multivariate predictors of metabolic syndrome.
Odds Ratio 95% Conﬁdence Interval P value
NCEP MS
Hypertension 955.1 9.1–100791.6 .004
Fasting Glucose 133.6 5.4–3317.7 .003
Triglycerides 8.0 1.4–45.6 .020
Waist Circumference 1.3 1.1–1.5 .004
HDL 0.003 0.000–0.256 .011
Male Gender 0.001 0.000–0.364 .024
IDF MS
Hypertension 12.1 3.2–44.9 <0.001
Fasting Glucose 2.3 1.2–4.3 .014
Waist Circumference 1.1 1.0–1.2 .001
HDL 0.07 0.01–0.64 .0186 Cardiology Research and Practice
these contemporary deﬁnitions in patients with AMI: 54%
according to the 2005 IDF deﬁnition and 49% according
to the 2001 NCEP deﬁnition. The prevalence of MS (by
eitherdeﬁnition)wasgreaterthananyotherstandardcardiac
risk factor in this population. There was a high degree
of concordance between the obesity-centric IDF and the
nonobesity centric NCEP deﬁnitions for the diagnosis of MS
(κ = 0.664, P<. 001). However, despite the markedly high
prevalence of MS in this high-risk population, there was a
low rate of clinical detection of MS by clinicians, raising
questions about the clinical utility of this syndrome in this
context.
Evolving understanding of MS has led to multiple
deﬁnitions over the years, with variable emphasis on the
role of insulin resistance in the pathophysiology of MS
[1, 2, 5]. The NCEP deﬁnition, for example, places equal
emphasis on all of the components comprising the cluster
of metabolic derangements rather than emphasizing either
insulin resistance or obesity [2, 11]. The IDF deﬁnition, by
contrast, is the ﬁrst to emphasize the measure of central
obesity over insulin resistance as the essential criterion
for MS diagnosis, and as such draws a vital connection
between the modern “obesity epidemic” and the metabolic
derangements seen in MS [5]. This represents an important
shift in the current understanding of MS, and has important
implications for both primary and secondary prevention of
coronary disease with respect to both obesity and MS. In
the current study, despite the relatively small sample size,
the number of features of MS other than central obesity
was noted to be higher in patients who exceeded the waist
circumference cutoﬀs( 2 . 2± 1.2 versus 1.5 ± 1.2, P = .028),
conﬁrming a potential causative role for central obesity.
Also, given that all patients with IDF MS had obesity by
deﬁnition,presenceoftheseadditionalMS-relatedmetabolic
derangements may be a way of reﬁning risk assessment in
obese patients.
ThediagnosisofMSfollowinganAMIposesseveralchal-
lenges. The physiological and psychological stress associated
with an AMI results in perturbations in key components of
MS, namely, the blood pressure, plasma glucose and serum
lipid levels [4, 12–14]. In addition, medications such as beta-
blockers and nitrates alter the blood pressure, and early
administration of statins may alter the lipid proﬁle, creating
further confounding in the parameters used to diagnose MS.
The design of the study protocol attempted to address some
of these limitations. Lipid proﬁle testing was performed the
morning after admission, within 24 hours of admission, to
minimize impact on serum levels. This approach is currently
recommended in major guidelines [15]. Fasting glucose
measurements were delayed to the morning of discharge
to allow glucose metabolism to stabilize following AMI.
Ap r e v i o u ss t u d yh a sv a l i d a t e dt h ei n t e g r i t yo fg l u c o s e
metabolism at the time of discharge and levels performed
3 months later [4]. Family doctors of all patients were
contacted, and where available, fasting glucose and lipid
levels obtained within the 12 months prior to the AMI were
used to determine MS status.
The introduction of waist circumference as the measure
of central obesity also imposes practical diﬃculties, as this
measurement is rarely obtained during routine clinical care,
in contrast to height and weight measurements, which
are routinely obtained. This has led to previous studies
substituting BMI for waist circumference when estimating
MS prevalence utilizing data accumulated from institutional
databases [16]. However, this does not estimate the true
prevalence, and exposes the limitations of estimating MS
prevalence from conventionally recorded data. In the present
study, the prospective study design enabled targeted anthro-
pometric measurements in all study patients, allowing for a
more accurate quantiﬁcation of the point prevalence of MS.
MS was more prevalent in this population than any
other standard cardiac risk factor. This raises the possibility
that population screening for MS may therefore identify
patients at high risk for acute coronary syndromes more
eﬀectivelythanstandardcardiacriskfactors.Previousstudies
which have examined the prevalence of MS in the general
population have reported a prevalence of 20–30% in the
adult population [11, 17], compared to the prevalence of
approximately 50% in the AMI cohort included in the
present study. In the San Antonio Heart Study, MS according
to the NCEP deﬁnition was an independent predictor of car-
diovascular mortality after adjustment for age, gender, and
ethnic group [2]. There was also an important association
between female gender and MS by the NCEP criteria in the
present study. The population included in the current study
represents a high-risk population with a high-cardiovascular
mortality. In the San Antonio Heart Study females with
MS had nearly twice the risk for cardiovascular mortality
compared to males [2]. The higher mortality risk of women
compared to men with coronary disease is well recognized,
and MS may well be a method to further reﬁne risk
stratiﬁcation for women.
The failure of clinicians to recognize and incorporate MS
status into the process of routine clinical management of
patients raises further questions about the clinical validity
of this syndrome. Recently, several clinicians and scientists
have raised concerns about the clinical validity of this
syndrome [18–21]. It is likely that controversies about
the etiology of MS and its clinical validity, coupled with
the practical diﬃculties in assessing MS status discussed
above, limit clinical uptake of this syndrome in this setting.
However, it must be noted that while the diagnosis of MS
per se did not appear to be widely recognized clinically,
its components were recognized and clinically managed as
indicated, most patients were placed on statins following
their AMI regardless of lipid proﬁle; new medication for
diabetes was started in 5 patients (5%); ACE-inhibitors
and/or beta blockers were prescribed in the majority of
patients prior to discharge.
Echocardiographic indices of diastolic function revealed
greater diastolic impairment in patients with MS even
though there were no diﬀerences in rates of successful
reperfusion or indices of systolic function. The diastolic
dysfunction is most likely the result of the higher preponder-
ance of pre-existing hypertension/raised blood pressure and
diabetes in patient with MS. Hypertensive cardiomyopathy
in its various stages has a predominant impact on diastolic
rather than systolic function. Similarly, diabetic patientsCardiology Research and Practice 7
also exhibit a degree of diastolic impairment related to
microvascular dysfunction [22].
5. Limitations
This study has a number of key limitations. The number of
patientsenrolledinthisprospectivesinglecenterstudyrepre-
sents a relatively small sample size. Thus the prevalence data
obtained in this study should be interpreted with caution. As
discussed previously, there are fundamental issues associated
with the assessment of blood pressure,gluco-metabolic state,
and lipid indices in the peri-myocardial infarct period.
However, several design features of the study protocol
attempted to limit the impact of these confounding factors.
The number of women in the study was limited, which may
limit the clinical signiﬁcance of important gender associated
diﬀerences found in the present study. The small proportion
of non-Europid patients limits the generalization of results
to other ethnic groups who may be more susceptible to the
metabolic syndrome. Finally, while this study has focused on
the prevalence and clinical management of MS in patients
with AMI, the long-term prognostic implications of MS in
thesepatientshavenotbeenexamined.Thelackoffollow-up
datawithrespecttohardclinicalendpointsafterasubstantial
follow-up period limits the conclusions that can be drawn
from this study about the clinical signiﬁcance of the MS in
patients with AMI.
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